{
    "title": "Exploring the Generalization of Cancer Clinical Trial Eligibility Classifiers Across Diseases",
    "abstract": "arXiv:2403.17135v1 Announce Type: new  Abstract: Clinical trials are pivotal in medical research, and NLP can enhance their success, with application in recruitment. This study aims to evaluate the generalizability of eligibility classification across a broad spectrum of clinical trials. Starting with phase 3 cancer trials, annotated with seven eligibility exclusions, then to determine how well models can generalize to non-cancer and non-phase 3 trials. To assess this, we have compiled eligibility criteria data for five types of trials: (1) additional phase 3 cancer trials, (2) phase 1 and 2 cancer trials, (3) heart disease trials, (4) type 2 diabetes trials, and (5) observational trials for any disease, comprising 2,490 annotated eligibility criteria across seven exclusion types. Our results show that models trained on the extensive cancer dataset can effectively handle criteria commonly found in non-cancer trials, such as autoimmune diseases. However, they struggle with criteria disp",
    "link": "https://arxiv.org/abs/2403.17135",
    "context": "Title: Exploring the Generalization of Cancer Clinical Trial Eligibility Classifiers Across Diseases\nAbstract: arXiv:2403.17135v1 Announce Type: new  Abstract: Clinical trials are pivotal in medical research, and NLP can enhance their success, with application in recruitment. This study aims to evaluate the generalizability of eligibility classification across a broad spectrum of clinical trials. Starting with phase 3 cancer trials, annotated with seven eligibility exclusions, then to determine how well models can generalize to non-cancer and non-phase 3 trials. To assess this, we have compiled eligibility criteria data for five types of trials: (1) additional phase 3 cancer trials, (2) phase 1 and 2 cancer trials, (3) heart disease trials, (4) type 2 diabetes trials, and (5) observational trials for any disease, comprising 2,490 annotated eligibility criteria across seven exclusion types. Our results show that models trained on the extensive cancer dataset can effectively handle criteria commonly found in non-cancer trials, such as autoimmune diseases. However, they struggle with criteria disp",
    "path": "papers/24/03/2403.17135.json",
    "total_tokens": 980,
    "translated_title": "探索癌症临床试验资格分类器在疾病间的泛化性能",
    "translated_abstract": "临床试验对于医学研究至关重要，自然语言处理可增强其成功，在招募方面有应用。本研究旨在评估资格分类在广泛临床试验范围内的泛化性能。从阶段3癌症试验开始，标记有七种资格排除条件，然后确定模型在非癌症和非阶段3试验中的泛化效果。为评估此问题，我们整理了五种试验类型的资格标准数据：（1）其他阶段3癌症试验，（2）癌症阶段1和2试验，（3）心脏病试验，（4）2型糖尿病试验和（5）任何疾病的观察性试验，跨七种排除类型共涵盖了2,490个已标注的资格标准。我们的结果显示，在广泛癌症数据集上训练的模型可以有效处理非癌症试验中常见的标准，如自身免疫疾病。然而，它们在处理诸如缺乏标准等标准时会遇到困难。",
    "tldr": "本研究评估了癌症临床试验资格分类器在不同疾病间的泛化性能，发现在广泛癌症数据集上训练的模型可以处理非癌症试验的标准，但在某些情况下仍然存在困难。"
}